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Abstract
Background: Cobalamin (Cbl) deficiency has been associated with various neuropsychiatric symptoms of different
severities. While some studies dedicated in structural neuroimaging credibly address negative impact of low Cbl
status, functional imaging reports are limited. We herein retrospectively review the correlation of Tc-99 m ethyl
cysteinate dimer single-photon emission computed tomography (Tc-99 m-ECD SPECT) and clinical presentations
among patients with low serum cobalamin (Cbl) status (<250 pg/ml).
Methods: Twelve symptomatic patients with low serum Cbl status were enrolled. Clinical presentations, Tc-99
m-ECD SPECT, and neuropsychological tests were reviewed.
Results: Dysexecutive syndrome (67 %), forgetfulness (50 %), attention deficits (42 %), and sleep disorders (33 %)
constituted the major clinical presentations. All patients (100 %) had temporal hypoperfusion on the Tc-99 m-ECD
SPECT. Five patients (42 %) had hypoperfusion restricted within temporal regions and deep nuclei; seven patients
(58 %) had additional frontal hypoperfusion. In patients with hypoperfusion restricted within temporal regions and
deep nuclei, psychiatric symptoms with spared cognition were their main presentations. Among patients with
additional frontal hypoperfusion, six of seven patients (86 %) showed impaired cognitive performances (two of them
were diagnosed as having dementia). Among ten patients who finished neuropsychological tests, abstract thinking
(70 %) was the most commonly affected, followed by verbal fluency (60 %), short-term memory (50 %), and attention
(50 %). Anxiety and sleep problems were the major clinically remarkable psychiatric features (33 % both). Four Tc-99
m-ECD SPECT follow-up studies were available; the degree and extent of signal reversal correlated with cognitive
changes after Cbl replacement therapy.
Conclusions: Our TC-99 m-ECD SPECT observations provide pivotal information of neurobiological changes within
basal ganglia and fronto-temporal regions in conjunction with disease severity among patients with Cbl deficiency.
Hypoperfusion within thalamus/basal ganglia and temporal regions may be seen in the earlier state of Cbl deficiency,
when psychiatric symptoms predominate. Hypoperfusion beyond thalamus/basal ganglia and involving frontal regions
appears when cognitive problems, mostly dysexecutive syndrome, are manifested. Symmetric hypofrontality of SPECT
in the context of dysexcutive syndrome serves as a distinguishing feature of non-amnestic mild cognitive impairment
attributed to Cbl deficiency. Concordant with TC-99 m-ECD SPECT findings, the psychiatric symptoms and dysexcutive
syndrome undergird impaired limbic and dorsolateral prefrontal circuits originating from basal ganglia respectively.
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Background
Cobalamin (Cbl) deficiency has been associated with
various neuropsychiatric symptoms of different severities
[1]. Delayed detection of Cbl deficiency among the eld-
erly is sometimes complicated with severe neurological
consequences; hence determination of Cbl status is often
included in the diagnostic workup for dementia [2].
Serology evaluations of Cbl level are also frequently en-
listed as part of diagnostic repertoire for mild cognitive
impairment (MCI), an increasingly-identified syndrome
in which changes of cognition exist but not to the extent
of dementia [3]. Although previous literatures have ad-
dressed the negative impact of low Cbl status on myelin
formation, cellular membrane stability, and neurotrans-
mitters regulation [4], the causality between cognition
decline and Cbl status remains inconclusive [1]. As sub-
tle neuropathological changes in the brain may precede
profound symptoms or clinical dementia, neuroimaging
study provides a useful tool to probe fundamental mech-
anisms of disease process. While some studies dedicated
in structural neuroimaging credibly address negative im-
pact of low Cbl status [5, 6], functional imaging reports
are limited [7, 8]. Therefore, we conducted a surveillance
to integrate the clinical presentations and Tc-99 m ethyl
cysteinate dimer single-photon emission computed
tomography (Tc-99 m-ECD SPECT) among patients
with low Cbl status.
Methods
We retrospectively reviewed twelve symptomatic patients
with low serum Cbl status (<250 pg/ml) [9]. Their main
symptoms were featured with cognitive (e.g., forgetfulness
and difficulty on planning) and/or psychiatric (e.g., sleep
problems and low mood) complaints. All patients had
checked complete blood count, thyroid function, cortisol,
serum folic acid levels, and rapid plasma reagin screen,
which were within normal limits. All patients received
brain magnetic resonance imaging (MRI) for excluding
cerebral vascular occlusion and/or large cortical infarcts,
which would be possible confounding factors to SPECT
observations. Tc-99 m-ECD SPECT scan interpretations
and clinical profiles, including demographic data and
neuropsychological tests, were collected. The written
informed consent was obtained from all participants
and there relevant radiation exposure was under regu-
lation of radiometry in our country. The study was
permitted by the Institutional Review Board of the
Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical
Foundation (REC 103–47).
Tc-99 m-ECD SPECT
Twelve patients underwent a Tc-99 m-ECD SPECT scan
at rest, conducted before or one week within the start of
Cbl supplement. A brain scintigraphy was performed
30 min after intraveneous injection of 740 Mbq 99mTc-
ECD on General Electric, Infinia Hawkeye 4. Subse-
quently, a combined SPECT equipped with a dual-head
gamma-camera with low-energy high resolution collima-
tors, a 7 % energy window centered at 140 keV and 128 ×
128 matrix (GE, USA) was conducted. Acquisition was
performed in continuous mode with 240 projections in a
128 × 128 matrix, zoom:1. The camera operated in
segmented mode with double 360*2゜rotation with 3゜
per projection angle. No scatter windows were placed.
Through the mathematical approximation technique, ac-
quired data were reconstructed (ordered-subset expect-
ation maximization attenuation scatter method; Chang
order 0; threshold 10; coefficient 0.11; cutoff frequency,
0.3 cycles/pixel for the main) after applying a Butterworth
filter. The SPECT was displayed on GE Xeleris 2 worksta-
tion in axial, sagittal, and coronal slices. A count differ-
ence cost function with an iterative downhill-simplex
search algorithm was applied for registration. The images
were displayed on a computer monitor using an identical
cool color scale (window, 100; base, 0).
Both visual and quantitative image analyses were
performed. For visual analysis, images were reported
independently by two nuclear medicine physicians who
were blind to radiological and clinical results. Should
there be any discrepancy between the interpretations, a
consensus would be reached after panel discussion. For
the quantitative analysis, 4 fixed axial images with prede-
fined templates were selected (Fig. 1). Ten regions of
interest, including six in bilateral cerebral cortices
(frontal, temporal, and parietal regions) and four in deep
nuclei (thalamus and basal ganglia), were symmetrically
analyzed in each hemisphere. The regions of interest
ranged in pixels from 90 (deep nuclei) to 170 (cerebral
cortices) and were fixed in size across studies. All
regions of interest were placed by the same operator to
eliminate interoperator variability. The intraoperator
reliability in the quantitative measurements was found
to be Kappa = 0.821 (p < 0.001), 95 % CI (0.602, 1.040)
(n = 12 times). The mean counts in each selected region
were normalized with respect to the mean counts in the
ipsilateral cerebellum to quantify regional ECD uptake.
In order to represent regional signal changes and avoid
selection bias, final ECD uptake would be calculated by
averaging data in which templates were placed onto
three sequential neighboring slices. The average values
of regions of interest to cerebellum ratio less than 0.8
were defined as abnormal and recorded [10].
Neuropsychological tests
Neuropsychological tests were available in ten patients.
Mini-mental state examination (MMSE) [11], Cognitive
Abilities Screening Instrument (CASI) [12], Clinical
Dementia Rating (CDR) [13], and neuropsychiatric
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inventory (NPI) [14] were thoroughly reviewed. In both
MMSE and CASI, higher score represents better cogni-
tive achievement. A MMSE score less than 26 would
conventionally be classified as indicative of cognitive im-
pairment [11]. CASI total scores below the cut-off score
of normative data in Taiwan were registered as abnormal
[15]. Additionally, CASI provides quantitative assess-
ment of 9 cognitive subdomains, including long term
memory, short term memory, attention, mental manipu-
lation, orientation, abstract thinking, language abilities,
drawing, and verbal fluency. Scores of CASI subdomain
falling more than one standard deviation of normative
data in Taiwan were registered as abnormal [15]. CDR
was applied to evaluate the daily functional performance
related with the severity of cognitive deficits (0 = Normal;
0.5 = Very mild; 1 =Mild; 2 =Moderate; 3 = Severe). NPI,
in which twelve psychological symptoms were determined,
were registered clinically-remarkable if score of each
defined symptom more than 4 [14].
Results
Tc-99 m-ECD SPECT
Tc-99 m-ECD SPECT findings in line with clinical profiles
were summarized in Table 1. The patients’ age ranged
from 29 to 81. Dysexecutive syndrome (67 %), forgetful-
ness (50 %), attention deficits (42 %), and sleep disorders
(33 %) constituted the major clinical presentations. All
patients (100 %) had temporal hypoperfursion on the Tc-
99 m-ECD SPECT. Five patients (42 %) (Patient #8 ~ #12)
had hypoperfusion restricted within temporal regions and
deep nuclei; seven patients (58 %) (Patient #1 ~ #7)
had frontal hypoperfusion in addition to temporal hy-
poperfusion. In patients with hypoperfusion restricted
within temporal regions and deep nuclei, their cogni-
tive performances were intact (MMSE = 26 ~ 27;
CASI = 75 ~ 93) and daily functional performance
were relatively preserved (CDR = 0 ~ 0.5). Three of
five patients (60 %) presented with psychiatric symp-
toms (i.e., irritability, anxiety, and sleep disorders).
Among patients with additional frontal hypoperfusion,
six of seven patients (86 %) showed impaired cogni-
tive performances (MMSE = 12 ~ 25; CASI = 34 ~ 82)
and impaired daily functional performance (CDR =
0.5 ~ 1). Only one patient had normal achievement of
neuropsychological tests and intact daily functional
status (Patient #7). Dysexecutive syndrome (86 %)
and attention deficits (57 %) constituted the major
clinical presentations. Anxiety and insomnia were re-
corded in three patients (43 %). Two patients (29 %)
were eventually diagnosed with dementia.
Quantitative assessment of Tc-99 m-ECD SPECT
was detailed in Table 2. Data were presented as indi-
vidual value of three consecutive slices and their aver-
age. From the data of cerebral cortices, abnormal
ratio counts within temporal regions were identified
in all patients (eleven as bilateral and one as unilat-
eral involvement). Abnormal ratio counts within
frontal regions were identified in seven patients (Pa-
tient #1-#7); all presented as bilateral involvement.
From the data of deep nuclei, ten had impaired ratio
count within thalamus (eight as bilateral and two as
unilateral involvement). Five had impaired ratio count
within basal ganglia.
Intriguingly, Tc-99 m-ECD SPECT changed in accord-
ance with different clinical severity. In Patients #11 and
#12, whose CDR staged 0 and ages were younger, had
neuropsychiatric symptoms and hypoperfusion within
temporal regions on Tc-99 m-ECD SPECT. Among
cases whose CDR staged 0.5 or greater, hypoperfu-
sions of dorsolateral prefrontal regions turned to be
prominent as dysexcutive symptoms and attention
deficits prevailed (Fig. 2).
Neuropsychological tests
Ten patients who received complete neuropsychological
tests (Patient #1 ~ #10) were further analyzed. Abstract
thinking (70 %) was the cognitive domains most com-
monly affected, followed by verbal fluency (60 %), short-
term memory (50 %), and attention (50 %) (Fig. 3). In
NPI evaluations, there were three patients identified as
having clinically remarkable anxiety and sleep problems
(30 %). Only one patient had clinically remarkable
Fig. 1 Regions-of-interest templates placed on selected axial images of
single-photon emission computed tomography (SPECT). (a) F = frontal
regions; P = parietal regions. (b) T = temporal regions; BG = basal ganglia.
(c) Th = thalamus. (d) CE = cerebellum
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depression (10 %). Six patients were re-examined neuro-
psychological tests 3 months later after Cbl replacement
therapy, when normalization of serum Cbl level was
achieved. Three of them had improvement (Patient #3:
24 to 28; Patient #7: 28 to 30; Patient #8: 27 to 29)
but the other three (Patient #1: 12 to 11; Patient #6:
21 to 18; Patient #10: 27 to 23) had decline of MMSE
total score.
Tc-99 m-ECD SPECT follow-up studies
Tc-99 m-ECD SPECT follow-up studies were available in
four patients. They were proceeded three to five months
after Cbl replacement therapy (Patient #1: 5 months;
Patient #3: 5 months; Patient #7: 5 months; Patient #8:
3 months). In visual assessment, signals reversal was
identified within most regions that were originally
impaired, the extent and degree of signal reversal corre-
lated with individual therapeutic responses (Fig. 4).
In quantitative assessment of cerebral cortices (Table 3),
Patient #3, #5, #7 had global post-treatment increase over
baseline value compared with Patient #1, who had
increased value limited within right fronto-temporal and
bilateral parietal regions. Patient #3, #5, #7 also had more
intense post-treatment increase within fronto-temporal
regions than Patient #1. In the assessment of deep nuclei,
although all patients had signal increase, only Patient #7
and #8 had signal normalization.
Discussion
The aim of this work is to elucidate TC-99 m-ECD SPECT
findings in conjunction with clinical presentations and
symptom severity among patients with Cbl deficiency. The
selective involvement at bilateral fronto-temporal regions




















1 73/F 0 199 1 12 34 Bil. F. T. P. Tha.







2 80/F 0 230 1 13 42 Bil. F. T. Tha. Rt BG Forgetfulness
and dementia
3 60/F 6 207 0.5 24 78 Bil. F. T. Tha. Insomnia, forgetfulness,
attention deficits, and
dysexcutive syndrome
4 81/M 12 177 0.5 25 82 Bil. F. T. Tha.BG





5 53/F 6 218 0.5 22 65 Bil. F. T. Tha. Dysexecutive
syndrome, anxiety, and
insomnia




7 58/F 12 210 0 28 88 Bil. F. T. Tha. Anxiety, insomnia, and
dysexcutive syndrome
8 56/F 12 229 0.5 27 87 Bil. T. Tha. Dysexecutive
syndrome
9 65/F 6 202 0.5 26 93 Bil. T. Rt Tha. Attention deficits





11 29/F 12 199 0 N.A. N.A. Lt T. Tha. Irritability, anxiety,
dysthymia, and sleep
disorders
12 41/M 12 175 0 N.A. N.A Bil. T. Rt BG Anxiety
Abbreviations: F Famale, M: Male, N.A non-available, Bil bilateral, Rt right, Lt left, F frontal region, T temporal region, P parietal region, Tha thalamus, BG basal ganglia
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Table 2 Regions-to-cerebellar ratio among patients with cobalamin deficiency
Frontal regions Temporal regions Parietal regions Thalamus Basal ganglia
Rt Lt Rt Lt Rt Lt Rt Lt Rt Lt
Patient #
1 .81 .77 .78 .82 .80 .76 .80 .78 .79 .75 .75 .71 .79 .78 .79 .79 .79 .80 .76 .75 .79 .72 .73 .68 .82 .82 .81 .74 .74 .74
.79 .79 .79 .74 .79 .79 .77 .71 .82 .74
2 .78 .80 .80 .74 .74 .75 .79 .81 .78 .73 .74 .76 .95 .92 .95 .82 .82 .80 .72 .72 .71 .70 .71 .72 .72 .70 .71 .80 .81 .81
.79 .74 .79 .74 .94 .81 .72 .71 .71 .81
3 .76 .80 .81 .80 .80 .76 .75 .75 .76 .76 .78 .81 .99 1.01 .99 .95 .95 .99 .73 .72 .73 .68 .68 .68 .96 .95 .96 .92 .93 .93
.79 .79 .75 .78 1.00 .96 .73 .68 .96 .93
4 .68 .67 .72 .78 .77 .77 .76 .75 .76 .77 .78 .78 .89 .87 .85 .92 .95 .94 .73 .76 .76 .78 .78 .78 .61 .63 .67 .78 .77 .74
.72 .77 .76 .78 .87 .94 .75 .78 .64 .76
5 .76 .76 .80 .73 .80 .77 .75 .75 .71 .77 .76 .76 .82 .82 .86 .83 .82 .83 .77 .78 .78 .67 .66 .72 .83 .84 .83 .82 .82 .82
.77 .77 .74 .76 .83 .83 .78 .68 .83 .82
6 .75 .77 .80 .80 .75 .83 .78 .78 .80 .77 .76 .77 .95 .93 .94 .94 .95 .96 .78 .78 .80 .78 .79 .79 .89 .87 .87 .86 .85 .88
.77 .79 .79 .77 .94 .95 .79 .79 .88 .86
7 .78 .80 .76 .79 .77 .77 .75 .75 .74 .75 .75 .73 .85 .87 .85 .84 .81 .83 .67 .69 .69 .69 .69 .70 .91 .92 .94 .93 .95 .93
.78 .78 .75 .74 .86 .83 .68 .69 .92 .94
8 .84 .88 .87 .90 .92 .88 .75 .70 .70 .79 .79 .79 .90 .89 .89 .92 .92 .93 .71 .69 .72 .79 .82 .75 .91 .90 .87 .96 .95 .96
.86 .90 .72 .79 .89 .92 .71 .79 .89 .96
9 .86 .87 .85 .97 .92 .94 .77 .77 .77 .80 .79 .79 .82 .83 .82 .97 .94 .97 .66 .65 .64 .83 .83 .83 .94 .92 .92 .96 .99 .95
.86 .94 .77 .79 .82 .96 .65 .83 .93 .97
10 .90 .89 .88 .83 .83 .83 .79 .75 .76 .68 .74 .78 .98 .95 .98 .79 .86 .89 .80 .80 .80 .81 .81 .79 .85 .81 .88 .80 .79 .79
.89 .83 .77 .73 .97 .85 .80 .80 .85 .79
11 .93 .92 .86 .83 .88 .90 .82 .82 .81 .72 .72 .72 .98 1.02 1.00 .95 .85 .91 .86 .84 .80 .77 .72 .74 .98 .99 1.00 .95 .93 .95
.90 .87 .82 .72 1.00 .90 .83 .74 .99 .94
12 .86 .92 .94 .91 .90 .87 .78 .74 .76 .77 .71 .74 .98 .98 .98 .97 .97 .98 .81 .81 .81 .79 .80 .80 .75 .75 .75 .87 .84 .87
.91 .89 .76 .74 .98 .97 .81 .80 .75 .86












seems to be the most consistent TC-99 m-ECD SPECT
findings in Cbl-deficient patients. Prefrontal lesions com-
monly refer to executive dysfunction and vice versa [16].
Our cohort associates dysexecutive syndrome and atten-
tion deficits with hypofrontality of TC-99 m-ECD SPECT.
It’s the case that our patients with low serum Cbl status
frequently encountered difficulty in planning personal
agenda, managing situations of daily life, and tolerating
changes of routine. There is a wealth of evidences suggest-
ing roles of prefrontal regions in abstract thinking, verbal
fluency, executive dysfunction, and attention maintenance
[17, 18]. The attention recruitment, highly allied with
execution network, implement newly-generated schema
and later assess their accuracy whenever an individual en-
counter a novel situation [19]. Moreover, it is hypothesized
that the prefrontal cortex serves a specific function in cog-
nitive control, in which patterns of activity that represent
goals were actively maintained by shifting attention of all
sensory modalities [20]. While prefrontal areas are pivotal
for executive function and attention control, several other
regions, including basal ganglia [18], thalamus, and cingu-
late gyrus are frequently recruited to accomplish implemen-
tation of such function [21]. The dorsolateral prefrontal
circuits, as one of the major connections originating from
the basal ganglia, govern implicit learning, sequencing, and
allocation and filtering of attention [22]. These opera-
tions would be allocated in enhancing the efficiency
of higher order processors such as execution, motor
planning, and mental manipulation. Deactivation of basal
ganglia would impair activity of frontal regions through
dorsolateral prefrontal circuits, leading dysexecutive
syndrome among Cbl-deficient patients.
Our TC-99 m-ECD SPECT also addresses the clinical
importance of hypoperfusion within temporal lobes.
While lateral and ventral portions of temporal lobe govern
sensory input processing, medial portion of temporal lobe
has been linked to encoding process of memory acquisi-
tion [23]. It is therefore reasonable to expect short-term
memory deficits during the neuropsychological tests.
Aside from the roles on cognition, there are prolific evi-
dences of SPECT associating temporal lobe with various
psychiatric symptoms [24]. The limbic circuits of basal
ganglia, constituted by reciprocal projections between
ventral part of striatum and temporal lobe, have also been
approved of great impact on psychiatric disorders [22].
Two young patients in our studies (Patient #11 and #12),
whose ages are far below commonly-known neurodegen-
erative diseases, address the negative impact of Cbl defi-
ciency on cerebral metabolism. They often prone to worry
about things that are not general cause for concern. From
our cohort of patients with low Cbl status, anxiety and
sleep problems are the major psychiatric features, and
symptoms of anxiety and irritability might predate cogni-
tive decline. By incorporating hypofunction of basal
ganglia and fronto-temporal regions as the evidences of
neurobiological abnormalities, distortion of cognition
would further predispose anxiety and irritability, making
patients with Cbl deficiency more vulnerable to react with
changes of environmental stimuli.
We are convinced that TC-99 m-ECD SPECT evalua-
tions not only provide neurobiological measures to under-
gird clinical phenomenology but serve as a supplementary
tool for the workup of patients with cognitive decline.
Frontal regions deactivation might serve as a surrogate
Fig. 2 Single-photon emission computed tomography (SPECT) correlates with clinical presentations and disease severity of cobalamin-deficient
patients. (a) A case with anxiety disorder but preserved cognition. Clinical Dementia Rating (CDR) = 0. SPECT shows hypoperfusion in right basal
ganglia (asterisk) and bilateral temporal tips (arrow heads; Patient #12). (b) A case with prominent dysexecutive syndrome. CDR = 0.5. SPECT shows
hypoperfusion in right basal ganglia (asterisk) and left dorsolateral prefrontal cortex, in addition to temporal regions. (arrow heads; Patient #4).
(c) A case with clinical diagnosis of dementia. CDR = 1. SPECT shows bilateral, more pronounced in the left, thalamus (asterisk) and fronto-temporal
regions hypoperfusion (arrow heads; Patient #1)
Tu et al. BMC Neurology  (2015) 15:251 Page 6 of 11
marker for differentiating Cbl deficiency from Alzheimer’s
disease, in which radiouptake in precuneus, posterior
cingulate gyrus, parietal and medial temporal lobes are
preferentially impaired [24, 25]. Moreover, characterizing
SPECT patterns would be of paramount clinical value be-
fore clinically-overt dementia occurs. Our study describes
cognitive decline in a wide spectrum of severity, although
the majority of our patients are categorized as MCI given
with objective cognitive deficits but substantially preserved
daily functional autonomy. Current researches frequently
dichotomize MCI into amnestic and non-amnestic sub-
types by neuropsychological tests. In contrast to the latter,
amnestic subtype of MCI has greater possibility to share
Alzheimer’s disease pathology as it preludes demented
Fig. 3 Characterization of cognitive profiles of patients with low cobalamin status
Fig. 4 Single-photon emission computed tomography (SPECT) signal changes in relation to cobalamin replacement therapy. (a) A demented
patient with no improvement in cognition after therapy [Mini-Mental State Examination (MMSE) = 12 to 11] had minimal signal regain only within
temporal regions. (arrow heads; Patient #1) (b) A mildly cognitive impaired patient with improvement in cognition after therapy (MMSE = 24 to 28)
had avid SPECT signal recovery within bilateral fronto-temporal regions.(arrow heads; Patient #3) (c) A patient with improvement of initial
dysexecutive complaints and anxiety after therapy (MMSE = 28 to 30) had improving signals within bilateral thalamus (asterisk) and fronto-temporal
regions.(arrow heads; Patient #7) (d) A mildly cognitive impaired patient with improvement in cognition after therapy (MMSE = 27 to 29) had improving
perfusion within bilateral thalamus (asterisk) and temporal regions from the follow-up SPECT. (arrow heads; Patient #8)
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Table 3 Regions-to-cerebellar ratio changes in relation to cobalamin replacement therapy
Frontal regions Temporal regions Parietal regions Thalamus Basal ganglia
Rt Lt Rt Lt Rt Lt Rt Lt Rt Lt
Patient#
1 before .81 .77 .78 .82 .80 .76 .80 .78 .79 .75 .75 .71 .79 .78 .79 .79 .79 .80 .76 .75 .79 .72 .73 .68 .82 .82 .81 .74 .74 .74
.79 .79 .79 .74 .79 .79 .77 .71 .82 .74
1 after .79 .81 .81 .76 .76 .80 .89 .87 .88 .77 .77 .75 1.04 1.05 1.05 .95 .93 .91 .79 .78 .78 .72 .72 .72 .85 .84 .85 .74 .74 .74
.80 .77 .88 .76 1.05 .93 .78 .72 .85 .74
3 before .76 .80 .81 .80 .80 .76 .75 .75 .76 .76 .78 .81 .99 1.01 .99 .95 .95 .99 .73 .72 .73 .68 .68 .68 .96 .95 .96 .92 .93 .93
.79 .79 .75 .78 1.00 .96 .73 .68 .96 .93
3 after .92 .92 .90 .87 .87 .87 .92 .92 .93 .90 .86 .86 1.00 1.01 1.01 .96 .97 .98 .73 .73 .72 .74 .75 .75 .94 .94 .94 .93 .93 .92
.91 .87 .92 .87 1.01 .97 .73 .75 .94 .93
7 before .78 .80 .76 .79 .77 .77 .75 .75 .74 .75 .75 .73 .85 .87 .85 .84 .81 .83 .67 .69 .69 .69 .69 .70 .91 .92 .94 .93 .95 .93
.78 .78 .75 .74 .86 .83 .68 .69 .92 .94
7 after .88 .88 .82 .88 .86 .87 .81 .81 .81 .87 .84 .84 .85 .87 .88 .86 .87 .86 .80 .81 .80 .83 .82 .82 .84 .85 .86 .88 .88 .87
.86 .86 .81 .85 .87 .86 .80 .82 .85 .88
8 before .84 .88 .87 .90 .92 .88 .75 .70 .70 .79 .79 .79 .90 .89 .89 .92 .92 .93 .71 .69 .72 .79 .82 .75 .91 .90 .87 .96 .95 .96
.86 .90 .72 .79 .89 .92 .71 .79 .89 .96
8 after .93 .92 .94 .96 .96 .96 1.00 1.00 1.00 1.03 1.04 1.03 .95 .94 .95 1.02 1.01 .98 .86 .87 .86 .87 .87 .88 .90 .91 .91 .97 .97 .97
.92 .96 1.00 1.03 .95 1.00 .86 .87 .91 .97












state in a closer temporal relationship [26]. The analysis of
neuropsychological tests supports that non-amnestic
subtype of MCI constituted as the majority of our cohort,
whose TC-99 m-ECD SPECT features a pattern of sym-
metric hypoperfusion within frontotemporal regions. The
widespread cerebral blood flow decrement not only
stresses its relevance with metabolic derangement but also
provides an interesting contrast to recent SPECT reports
of MCI, where asymmetric hypoperfusion over frontal
regions and hippocampus occurs in association with non-
amnestic and amnestic subtypes, respectively [27].
Hypofrontality in our TC-99 m-ECD SPECT observations
also provides an interesting parallel to another cohort
study, in which predominant post-central cerebral blood
flow decrement with better preserved central and
prefrontal flow value is described among Cbl-deficient
patients with heterogenous dementia subtypes and super-
imposed delirium [28]. As all of our patients with cognitive
complaints are free of delirium and/or of psychotropic
medications before TC-99 m-ECD SPECT evaluations, the
linkage between functional neuroimaging and the cognitive
deficits relevant to Cbl deficiency would be more straight-
forward. Still, doubt on co-existing neurodegenerative dis-
ease in our cohort might exist. We regard Cbl deficiency
as the main causes of cognitive impairment in the current
study based onto their structural images are nearly normal.
While hypoperfusion of TC-99 m-ECD SPECT is
pronounced, the volume of brain parenchyma remains
fully preserved. Moreover, the signal reversal of follow-up
Tc-99 m-ECD SPECT after Cbl replacement therapy sup-
ports the linkage between low Cbl status and cerebral
metabolic changes. The extent and degree of signal reversal
of TC-99 m-ECD SPECT, in line with cognitive changes,
serves as useful internal control to validate our hypothesis.
There are several lines of mechanisms explaining
symptoms attributed to Cbl deficiency. First is the
derangement in the monoamine neurotransmitter, as
both Cbl and folic acid are prerequisites for its produc-
tion [4]. Second is impaired DNA synthesis by reducing
availability of tetrahydrofolate, the essential substance
maintaining cellular integrity [29]. Third is damages of ves-
sels and myelin secondary to acumination of homocysteine
and methylmalonic acid [30]. Given with nearly-normal
conventional MRI images in this study, we therefore
assume that neurotransmitter derangement and damage of
neuronal integrity contribute to the hypometabolism of
fronto-temporal regions on TC-99 m-ECD SPECT, as
regional cerebral blood flow has been regarded to reflect
synaptic activities [31]. Our hypothesis is also in line with
previous animal experiments, issuing Cbl deficiency would
impair cerebral glucose metabolism in cortical as well as
subcortical areas of the brain [32].
It’s also worth to point out that the metabolic derange-
ment among Cbl-deficient patients predates obvious
changes of structural neuroimaging, even among young
patients. In our cohort, there were two patients, aged 29
and 41, presented psychiatric symptoms and relevant
hypoperfusion restricted within temporal regions and
deep nuclei. These two patients, whose ages are much
younger than those of patients with neurodegenerative
disease, address evidences supporting negative impact of
Cbl deficiency toward central nervous system. Some
may speculate whether TC-99 m-ECD SPECT findings
are the epiphenomenon related to endogenous mood
disorders rather than the results relevant to Cbl defi-
ciency. Nonetheless, their low Cbl level raises the plaus-
ible explanation to their unusual presentations, which is
distinct from typical mood disorders. Moreover, half of
our patients with follow-up neuropsychiatric tests show
remarkable improvement after 3 months of Cbl supple-
ment therapy. The robust findings mirror the causality
between cognitive impairment and Cbl deficiency.
Although poor responders to Cbl supplement exist, such
findings don’t preclude the negative impact of low Cbl
state, as normalization of serum Cbl level doesn’t guar-
antee complete restoration of cellular reserve and
utilization process [1].
There are several limitations in our study. First, the
study was limited in its cross-sectional study design as
well as small sample size. Generalization of the results
warrants future prospective studies of greater case num-
ber. Comparison of SPECT findings between groups
with similar cognitive achievement but different Cbl
level would also of high research value to document
linkage between Cbl level and SPECT presentations.
Second, as excluding co-existing neurodegenerative
disease has always been a great challenge in the studies
related to Cbl deficiency, we had integrated brain MRI
into diagnostic consideration. We regard the possibility
of co-existing Alzheimer’s disease in our cohort is
limited, as our patients have no medial temporal lobe
atrophy, the pathological change typically observed in
Alzheimer’s disease or amnestic type of MCI. The signal
reversal after Cbl replacement also served as evidences
to corroborate that the underlying pathogenesis in our
cohort is related to Cbl deficiency. Third, the study of
other serology markers related to Cbl was not compre-
hensive in our study. Due to the fact that serum methyl-
malonic acid and homocysteine elevates earlier than the
serum Cbl decrement [33] and holotranscobalamin, the
biologically active Cbl, correlates with Cbl status in a
more sensitive manner [34, 35], application of these serum
markers in the future studies may provide further infor-
mation fundamental for changes of cerebral metabolism.
Last, although our TC-99 m-ECD SPECT evaluations
provided convincing evidences representing functional
derangement within selected regions, future studies,
preferably analyzing segregated anatomical regions, may
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be more straightforward underpinning cerebral metabolic
changes attributed to Cbl deficiency.
Conclusion
The retrospective review of our TC-99 m-ECD SPECT
observations provides pivotal information of neurobio-
logical changes within basal ganglia and fronto-temporal
regions in conjunction with disease severity among pa-
tients with Cbl deficiency. Hypoperfusion within basal
ganglia in addition to temporal regions may be seen in
the earlier state of Cbl deficiency, when cognition
remains intact but psychiatric symptoms predominate.
Hypoperfusion within basal ganglia in association with
frontal regions appears when cognitive problems, mostly
dysexecutive syndrome, are manifested. Symmetric
hypofrontality in association with dysexcutive syndrome
serves as a distinguishing feature of non-amnestic MCI
attributed to Cbl deficiency, in contrast to amnestic
MCI or Alzheimer’s disease. Concordant with TC-99 m-
ECD SPECT findings, the psychiatric symptoms and
dysexcutive syndrome undergird impaired limbic and
dorsolateral prefrontal circuits originated from basal
ganglia respectively. As prompt supplement reverses
cognitive deficits among certain portion of patients with
Cbl deficiency, judicious evaluation of Cbl status should
be highlighted among patients with non-amnestic MCI,
especially in the context of poor nutrition intake and/or
malabsorption.
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